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OR 95%CI P Cases (N) Cases (F) Phet I
2
Adenocarcinoma
  ICELAND 1.31 (1.11,1.53) 0.0010 538 0.837
  USA 1.05 (0.72,1.54) 0.79 67 0.776
  NETHERLAND 1.09 (0.84,1.41) 0.52 167 0.781
  SPAIN 0.87 (0.61,1.23) 0.42   82 0.713
COMBINED
a
1.17 (1.04,1.32) 0.0095 854 0.776 0.16   42.7
::::::::::::::
SMCC
  ICELAND 1.17 (0.93,1.48) 0.19 223 0.822
  NETHERLANDS 0.8 (0.50,1.27) 0.34 47 0.723
  SPAIN 0.93 (0.63,1.37) 0.72 70 0.729
COMBINED
a
1.05 (0.87,1.26) 0.63   340 0.758 0.28      20.7
::::::::::::::
SQCC
  ICELAND 1.24 (1.01,1.53) 0.04 309 0.83
  USA 0.87 (0.55,1.38) 0.55 52 0.741
  NETHERLANDS 1.06 (0.82,1.38) 0.64 177 0.777
  SPAIN 1.29 (0.96,1.73) 0.097 134 0.787
COMBINED
a
1.16 (1.02,1.33) 0.030  672 0.783 0.42   0
Supplementary table 1 - Association of rs748404-T with different histological subtypes of 
lung cancer
The frequency of rs748404-T in cases was compared with the frequency of the variant in control populations.  The 
frequencies in controls are as follows:  Iceland= 0.797, USA=0.766, Netherlands=0.766, Spain=0.742.  
a
For the combined study populations, the reported control frequency was the average, unweighted control 
frequency of the individual populations, while the OR and the P value were estimated using the Mantel-Haenszel 
model.
   
SNP P # cases # controls Overall freq Information Allele tested
rs2277532 0.000203258   839    36,606  0.683693 0.997003 G
rs12050604 0.000124821   837    36,550  0.686415 1.000000 C 
rs504417 0.0344518       839    36,558  0.300492 1.000000 G
rs471122 0.0317988      839    36,606  0.300853 0.999991 G
rs506120 0.403561        839    36,606  0.291453 0.996399 T
Supplementary table 2 - Association results for 5 SNPs reported by Landi et al.  in chip-typed 
Icelandic lung cancer cases and controls 
  
SNP D' r2 Chr Pos P*
rs12050604 0.42 0.13 C15 41,144,698       9.75×10
-6
rs2277532 0.43 0.14 C15 41,031,991       3.55×10
-6
rs471122 1.00 0.69 C15 41,345,866       1.59×10
-5
rs504417 1.00 0.69 C15 41,341,518       1.92×10
-5
rs506120 0.85 0.51 C15 41,589,316       4.25×10
-5
* P value reported in meta-analysis by Landi et al . 
Supplementary table 3 - LD between rs748404  and the 5 SNPs 
reported by Landi et al.
  
POPULATIONS P OR CI cases (N) cases (F) controls (N) controls (F) Phet I2
Results from meta-analysis
a
9.7×10
-6
1.09 (1.05, 1.13) 13,300 19,666
Follow-up sample sets:
     USA 0.482 1.1 (0.84, 1.44) 177 0.718  823 0.697
     The Netherlands 0.485 1.06 (0.90, 1.23) 506 0.710 1832 0.699
     Spain 0.289 1.12 (0.91, 1.37) 497 0.742  503 0.721
COMBINED follow up 0.17 1.08 (0.97, 1.21) 1,180 0.723 3,158 0.706 0.91 0
ALL COMBINED 3.6×10
-6
1.09 (1.05, 1.13) 14,480 22,824 0.98 0
Supplementary table 4 - Association between rs12050604-C and lung cancer in case control sample sets
a
 The meta-analysis reported by Landi et al. includes data from 719 cases and 6,030 controls from the Icelandic population, therefore Icelandic 
samples are not included among the fol low-up datasets for this SNP.
  
Population OR 95% CI P  value OR 95% CI P  value
          USA 1.22 (0.92, 1.62) 0.17 1.07 (0.82, 1.39) 0.62
          The Netherlands 1.05 (0.89, 1.24) 0.56 1.04 (0.88, 1.23) 0.64
          Iceland 1.12 (0.98, 1.28) 0.085 1.16 (1.05, 1.28) 0.003
          Spain 1.05 (0.88,1.25) 0.59 1.11 (0.91, 1.36) 0.31
COMBINED 1.09 (1.01,1.19) 0.037 1.12 (1.04, 1.21) 0.0028
Phet=0.76, I
2
 = 0 Phet=0.71, I
2 
= 0
Supplementary table 5 - Joint analysis of rs748404(T) and rs12050604(C)
rs748404(T) adjusted for rs12050604(C) rs12050604(C) adjusted for rs748404(T)
  
Supplementary table 6 - Association between the TP53BP1  missense variant rs2602141-T and lung cancer
POPULATIONS P OR CI95 cases (N) cases (F) controls (N) controls (F) Phet I
2
     Iceland
a
0.011 1.11 (1.02, 1.20) 1,417      0.72 36,260 0.70
     USA 0.329 1.13 (0.88, 1.46) 187         0.74 845 0.71
     The Netherlands 0.131 1.12 (0.97, 1.30) 531         0.7 1,829 0.68
     Spain 0.019 1.2 (1.03, 1.40) 542         0.68 1,087 0.64
     4 groups COMBINED
b
0.00015 1.13 (1.06, 1.20) 0.84 0
     Results from Truong et al. 0.001 1.08 (1.03, 1.13) 15,719   - 19,305 -
     Results from Rudd et al. 0.0009 1.18 (1.07, 1.30) 1,529      - 2,707 -
ALL COMBINED
b
8.6×10
-9
1.11 (1.07, 1.15) 0.56 0
Shown are the P values, allel ic odds-ratio (OR) and 95% CI based on the multiplicative model, the number (N) and the allel ic frequency (F) of the 
variant in cases and controls.  All  P values are two-sided. 
a
 Resul ts  for the Icelandic population were adjusted by the method of genomic control .
b
 For the combined s tudy populations , the reported control  frequency was  the average, unweighted control  frequency of the individua l  
populations , whi le the OR and the P va lue were estimated us ing the Mantel -Haenszel  model .
 Population (# cases/# controls) OR 95% CI P  value OR 95% CI P  value
          USA (195/867) 1.22 (0.84, 1.76) 0.30   1.03 (0.74, 1.44) 0.86   
          The Netherlands (533/1,832) 0.97 (0.78, 1.21) 0.80   1.14 (0.94, 1.39) 0.19   
          Iceland (959/36,277) 1.27 (1.09, 1.47) 0.0017   0.90 (0.79, 1.03) 0.12   
          Spain (552/1,442) 0.97 (0.78, 1.21) 0.79   1.19 (0.97, 1.46) 0.098   
COMBINED (2,239/40,418 1.12 (1.01, 1.24) 0.027   1.02 (0.93, 1.11) 0.74   
Phet=0.10, I
2
 = 51.3 Phet=0.079, I
2 
= 55.8
rs748404(T) adjusted for rs2602141(T)  rs2602141(T) adjusted for rs748404(T)
Supplementary table 7 - Joint analysis of rs748404(T) and rs2602141(T)
